Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Neutral 53.1%

Neg 0% Neu 53.1% Pos 0%

Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.